Your browser doesn't support javascript.
loading
Efficacy of chemotherapy on overall survival in metastatic sarcomatoid bladder cancer patients.
Tappero, Stefano; Sorce, Gabriele; Panunzio, Andrea; Hohenhorst, Lukas; Garcia, Cristina Cano; Piccinelli, Mattia Luca; Tian, Zhe; Parodi, Stefano; Chun, Felix K H; Graefen, Markus; Antonelli, Alessandro; De Cobelli, Ottavio; Saad, Fred; Shariat, Shahrokh F; Montorsi, Francesco; Suardi, Nazareno R; Borghesi, Marco; Terrone, Carlo; Karakiewicz, Pierre I.
Afiliação
  • Tappero S; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
  • Sorce G; Department of Urology, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
  • Panunzio A; Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genova, Italy.
  • Hohenhorst L; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
  • Garcia CC; Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Piccinelli ML; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
  • Tian Z; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy.
  • Parodi S; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
  • Chun FKH; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
  • Graefen M; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
  • Antonelli A; Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt am Main, Germany.
  • De Cobelli O; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
  • Saad F; Department of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy.
  • Shariat SF; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
  • Montorsi F; Department of Urology, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
  • Suardi NR; Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genova, Italy.
  • Borghesi M; Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt am Main, Germany.
  • Terrone C; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
  • Karakiewicz PI; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy.
Cent European J Urol ; 75(4): 352-356, 2022.
Article em En | MEDLINE | ID: mdl-36794025
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article